Approximately 50 – 74 % from the patients that receive antipsychotics present extrapyramidal secondary effects (ESP). They represent an important indicator of reducing the neuroprotection, significantly correlated with chronic deficient evolution. The atypical antipsychotics associate with a reduced risk of ESP towards the typical ones, due to the effects over other neurotransmitters. The primary endpoint of the study was to evaluate the incidence and severity of the adverse extrapyramidal effects at the administration of 8 of the atypical antipsychotics and an atypical antipsychotic (haloperidol). Design: a clinical, longitudinal, prospective, open, comparative study was done regarding the differences of security and tolerance between the atypical antipsychotics and the latter versus haloperidol. The study had been carried on for one year, on a group of 180 patients diagnosed with schizophrenia, according to the DSM IV-TR criteria. Groups of 20 patients were administered one of the atypical antipsychotics and a group of 20 patients was administered haloperidol. Results: The extrapiramidal syndromes that occurred during the treatment were of acute type: parkinsonian disorder, acute dyskinesia, pseudo-akathisia or akathisia. Their severity was quantified with the help of the specific scales of measuring the extrapyramidal syndrome. The statistical processing and interpreting of the study data was made with a specialized program IBM SPSS Statistics – 19. The percentage rates of mild and severe ESP occurred after the administration of each atypical antipsychotic were analyzed. These were compared with the percentage rates of ESP determined by haloperidol. Conclusions: the atypical antipsychotics determine less ESP than the haloperidol does; within the atypical antipsychotics there are differences of tolerance; there were no cases of DT or SNM registered.